Ever Supreme Bio Technology Co., Ltd Stock price

Equities

6712

TW0006712003

Pharmaceuticals

End-of-day quote Taipei Exchange 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
217.5 TWD -0.46% Intraday chart for Ever Supreme Bio Technology Co., Ltd +1.64% +11.25%
Sales 2023 * 758M 23.72M Sales 2024 * 785M 24.56M Capitalization 15.95B 499M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * 21 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 20.3 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 62.54%
More Fundamentals * Assessed data
Dynamic Chart
Ever Supreme Bio Technology Co., Ltd Announces to Distribute Dividends for the Period January 1, 2023 to December 31, 2023 CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Ever Supreme Bio Technology Co., Ltd announces an Equity Buyback for 2,000,000 shares, for TWD 1,070 million. CI
Ever Supreme Bio Technology Co., Ltd authorizes a Buyback Plan. CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Ever Supreme Bio Technology Co., Ltd Announces Cash Dividend, Payable on June 21, 2023 CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Ever Supreme Bio Technology Co., Ltd Announces Phase IIa IND for UMSC01 in Patients with Acute Myocardial Infarction Was Granted Permission by Taiwan FDA CI
Ever Supreme Bio Technology Co., Ltd Announces Submission of A Phase a IND for UMSC01 in Patients with Acute Myocardial Infarction to Taiwan FDA CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
More news
1 day-0.46%
1 week+1.64%
Current month-1.14%
1 month-1.36%
3 months+11.54%
6 months+8.75%
Current year+11.25%
More quotes
1 week
210.00
Extreme 210
222.00
1 month
202.00
Extreme 202
229.00
Current year
191.00
Extreme 191
229.00
1 year
170.00
Extreme 170
229.00
3 years
140.95
Extreme 140.9539
421.62
5 years
71.92
Extreme 71.9237
421.62
10 years
49.19
Extreme 49.1892
421.62
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-01-31
Director of Finance/CFO - 17-08-17
Chief Tech/Sci/R&D Officer - 19-03-03
Members of the board TitleAgeSince
Director/Board Member - 19-03-12
Director/Board Member 59 18-06-25
Director/Board Member - 18-06-25
More insiders
Date Price Change Volume
24-03-28 217.5 -0.46% 588,666
24-03-27 218.5 +2.58% 1,370,947
24-03-26 213 -1.16% 540,524
24-03-25 215.5 +2.86% 802,592
24-03-22 209.5 -2.10% 906,415

End-of-day quote Taipei Exchange, March 27, 2024

More quotes
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
217.5 TWD
Average target price
205.5 TWD
Spread / Average Target
-5.52%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Ever Supreme Bio Technology Co., Ltd - Taipei Exchange